<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003035</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065642</org_study_id>
    <secondary_id>P30CA051008</secondary_id>
    <secondary_id>GUMC-97018</secondary_id>
    <secondary_id>NCI-V97-1276</secondary_id>
    <nct_id>NCT00003035</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>A Pilot Trial Comparing Doxorubicin and Paclitaxel Induced Apoptosis in Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug and giving the drugs in different ways&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of doxorubicin with&#xD;
      paclitaxel in treating women who have locally advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the feasibility of obtaining serial biopsies in patients receiving&#xD;
      neoadjuvant chemotherapy for locally advanced breast cancer. II. Assess the feasibility of&#xD;
      performing assays of apoptosis and of markers that predict response on specimens obtained in&#xD;
      these patients. III. Correlate the results of the assays with clinical and pathologic&#xD;
      response rates. IV. Establish a baseline of change in apoptosis rates for future studies. V.&#xD;
      Obtain serial blood samples and tumor tissue for future biological studies.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified by pre or postmenopausal state&#xD;
      and T3 or T4 lesions. Arm I: Patients receive single agent doxorubicin by bolus infusion on&#xD;
      day 1. Dose repeats every 14 days for a total of four courses, provided absolute neutrophil&#xD;
      count (ANC) and platelet count remain in the appropriate range. Patients then receive&#xD;
      paclitaxel IV administered over 3 hours once every 14 days for a total of four courses,&#xD;
      provided ANC and platelet count remain in the appropriate range. Filgrastim (G-CSF)&#xD;
      subcutaneous treatment is started on day 3 of each course, and continued for 7 days, or until&#xD;
      ANC is greater than 10,000/mm3. Patients undergo serial core-needle breast biopsies or fine&#xD;
      needle aspirations prior to starting therapy and on day one of each course. Arm II: Patients&#xD;
      receive four courses of paclitaxel given once every 14 days. Patients then receive four&#xD;
      courses of doxorubicin given on day 1 every 14 days, provided ANC and platelet count are in&#xD;
      the appropriate range. G-CSF subcutaneous treatment is started on day 3 of each course, as in&#xD;
      Arm I. Patients undergo serial core-needle breast biopsies or fine needle aspirations prior&#xD;
      to starting and on day one of each course. Arm I and II: Upon completion of eight courses of&#xD;
      chemotherapy, patients undergo a surgical procedure to evaluate the extent of residual&#xD;
      disease and number of lymph nodes involved, and to achieve local control. Following surgery,&#xD;
      patients receive additional treatment at the discretion of the treating oncologist. Eligible&#xD;
      patients undergo further high dose chemotherapy with peripheral blood stem cell rescue; other&#xD;
      patients receive cyclophosphamide therapy. Patients receiving lumpectomies receive breast&#xD;
      irradiation. Patients receiving mastectomies might receive chest wall irradiation. Following&#xD;
      radiotherapy, hormone receptor positive patients may start tamoxifen therapy for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: An estimated 40 patients (20 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <completion_date type="Actual">June 2001</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven locally advanced breast cancer Unresected T3&#xD;
        or T4 lesion, OR Unresected T2 lesion if patient considered appropriate candidate for&#xD;
        neoadjuvant chemotherapy to enhance breast conservation Hormone receptor status: Not&#xD;
        specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified&#xD;
        Performance status: ECOG 0-2 Hematopoietic: WBC at least 3,500/mm3 Platelet count at least&#xD;
        100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal Renal: Creatinine no&#xD;
        greater than 1.5 times normal Cardiovascular: LVEF at least 50% (baseline MUGA) No history&#xD;
        of uncontrolled congestive heart failure At least 6 months since prior myocardial&#xD;
        infarction No unstable angina No uncontrolled hypertension Neurologic: No peripheral&#xD;
        neuropathy Other: Not pregnant or nursing No psychosis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytotoxic&#xD;
        therapy Endocrine therapy: No prior hormonal therapy for breast cancer Prior estrogen&#xD;
        replacement therapy allowed No concurrent steroid therapy Radiotherapy: Not specified&#xD;
        Surgery: See Disease Characteristics Other: No concurrent treatment for serious infection&#xD;
        (bacterial, viral, or fungal)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2004</study_first_posted>
  <last_update_submitted>March 22, 2011</last_update_submitted>
  <last_update_submitted_qc>March 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Claudine Isaacs, MD</name_title>
    <organization>Georgetown University</organization>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

